Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity-Reference-Cited by-同舟云学术

Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity

Published:2014-11-26 Issue:2 Volume:6 Page:604-616
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Takizawa Itsuhiro¹,Lawrence Mitchell G.¹,Balanathan Preetika¹,Rebello Richard¹,Pearson Helen B.²³,Garg Elika⁴⁵,Pedersen John⁶,Pouliot Normand²³,Nadon Robert⁵,Watt Matthew J.⁷,Taylor Renea A.⁷,Humbert Patrick²³⁸,Topisirovic Ivan⁴,Larsson Ola⁹,Risbridger Gail P.¹,Furic Luc¹

Affiliation:

1. Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia

2. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

3. Sir Peter MacCallum Department of Oncology, Melbourne University, Victoria, Australia

4. Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital and Departments of Oncology, Experimental Medicine and Biochemistry, McGill University, Montréal, Canada

5. Department of Human Genetics, McGill University, Montréal, Canada

6. TissuPath Pathology, Melbourne, Victoria, Australia

7. Department of Physiology, Monash University, Clayton, Victoria, Australia

8. Department of Pathology and Department of Biochemistry and Molecular Biology, the University of Melbourne, Parkville, Australia

9. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The implications of hormone treatment for cancer risk, screening and treatment in transgender individuals;Best Practice & Research Clinical Endocrinology & Metabolism;2024-09

2. MicroRNA signature of stromal-epithelial interactions in prostate and breast cancers;Experimental Cell Research;2024-08

3. The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens;Biomedicines;2024-07-23

4. The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression;Journal of Clinical Investigation;2024-04-16

5. Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis;Journal for ImmunoTherapy of Cancer;2023-09